南新制藥(688189.SH):2021年度預虧1億元-2億元
格隆匯1月28日丨南新制藥(688189.SH)公佈2021年年度業績預虧公吿,經公司財務部門初步測算,預計2021年年度實現歸屬於母公司所有者的淨利潤與上年同期相比,將出現虧損,實現歸屬於母公司所有者的淨利潤為-1億元到-2億元。預計2021年年度歸屬於母公司所有者扣除非經常性損益後的淨利潤為-1.15億元到-2.15億元。
業績變化的主要原因:
(一)主營業務影響:2021年度,國內新冠疫情持續且受國外輸入性變異毒株的影響,疫情防控形勢嚴峻。由於新冠與流感的發病症狀高度相似,均具有發熱、乾咳、乏力等症狀,終端醫療機構對發熱門診採取了強力的管控措施,人流量驟減,導致終端醫療機構對公司產品“力緯”(帕拉米韋氯化鈉注射液)的需求大減。受此影響,公司核心產品“力緯”在2021年的銷售收入較2020年減少約4.33億元,同比減少超過50%,直接減少毛利約3.5億元。
受國家仿製藥一致性評價政策的影響,公司產品“辛可”(辛伐他汀分散片)2021年的銷售收入較2020年減少約5,718萬元,同比減少62.57%。公司產品“可福樂膠囊”(頭孢克洛膠囊)2020年底進入國家醫藥產品集中採購目錄,2021年的銷售收入較2020年同比減少約6876萬元,同比減少67.67%。
公司其他產品在2021年銷售收入均較2020年呈現一定增長,但佔2021年銷售收入比例較低,對2021年銷售收入的貢獻有限。
(二)非經常性損益的影響:本期非經營性損益總額較2020年增加約751萬元,其中收到政府補助(或確認)金額較2020年增加約314萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.